2,3 DCPE displays anticancer agent properties and induces ERK activation. Causes apoptosis in many tumor cell lines and is known to specifically cleave caspase-8, caspase-3, caspase-9, and poly(ADP-ribose) polymerase in cancer cells, but not in human fibroblasts. Shown to reduce the protein level of Bcl-XL. Triggered cell death in OAW42-R ovarian carcinoma cells with inhibition of Bcl-2 expression and increased cytotoxic effect of cisplatin in OAW42-R resistant cells. 2,3-DCPE reported to induce S-phase arrest and upregulate p21.
1. Wu, S., et al. 2004. Cancer Res. 64: 1110-1113. PMID: 14871845
2. Zhu, H., et al. 2004. Oncogene 23: 4984-4992. PMID: 15122344
See how others have used 2,3-DCPE. Click on the entry to view the PubMed entry .
PMID: # 17276501 Villedieu, M. et al. 2007. Gynecol. Oncol. 105: 373-384.
PMID: # 15122344 Zhu, H. et al. 2004. Oncogene. 23: 4984-4992.
PMID: # 15334064 Zhu, N. et al. 2004. Oncogene. 23: 7545-7551.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.